News + Filings Transactions Holdings
All 13F 13D/G Other
|
ARCH Venture Fund VII, L.P.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/08/2022 |
SC 13G/A
| ARCH Venture Fund VII, L.P. has filed a Schedule 13D for 908 Devices, Inc. |
02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Arch Venture Fund VII LP reports a 21.9% stake in Unity Biotechnology, Inc. |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 17.7% stake in Syros Pharmaceuticals, Inc. |
02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 9.3% stake in Juno Therapeutics, Inc. |
02/13/2017 |
SC 13G/A
| Juno Therapeutics, Inc. reports a 10% stake in Juno Therapeutics, Inc. |
02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
02/11/2016 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
02/11/2016 |
SC 13G/A
| Juno Therapeutics, Inc. reports a 11.5% stake in Juno Therapeutics, Inc. |
02/11/2016 |
SC 13G/A
| Sage Therapeutics, Inc. has filed a Schedule 13D for Sage Therapeutics, Inc. |
|
|